FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression.
Genetic variation in fibroblast growth factor 20 (FGF20) has been associated with risk of Parkinson's disease (PD). Functional evidence suggested the T allele of one SNP, rs12720208 C/T, altered PD risk by increasing FGF20 and alpha-synuclein protein levels. Herein we report our association study of FGF20 and PD risk in four patient-control series (total: 1,262 patients and 1,881 controls), and measurements of FGF20 and alpha-synuclein protein levels in brain samples (nine patients). We found no evidence of association between FGF20 variability and PD risk, and no relationship between the rs12720208 genotype, FGF20 and alpha-synuclein protein levels.
Wider
Christian
C
Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA. wider.christian@mayo.edu
Dachsel
Justus C
JC
Soto
Alexandra I
AI
Heckman
Michael G
MG
Diehl
Nancy N
NN
Yue
Mei
M
Lincoln
Sarah
S
Aasly
Jan O
JO
Haugarvoll
Kristoffer
K
Trojanowski
John Q
JQ
Papapetropoulos
Spiridon
S
Mash
Deborah
D
Rajput
Alex
A
Rajput
Ali H
AH
Gibson
J Mark
JM
Lynch
Timothy
T
Dickson
Dennis W
DW
Uitti
Ryan J
RJ
Wszolek
Zbigniew K
ZK
Farrer
Matthew J
MJ
Ross
Owen A
OA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005346:Fibroblast Growth Factors / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000235:genetics*; D051844:alpha-Synuclein / Q000235:genetics*
C416003:FGF20 protein, human; D051844:alpha-Synuclein; D005346:Fibroblast Growth Factors